Evaluation of Prognostic Factors and Validation of Tumor Response Ratios after Neoadjuvant Chemotherapy in Patients with Breast Cancer

Tong Moon; Dong Hui Cho; Jung Min Youn; Jae Bok Lee; Jeoung Won Bae; Seung Pil Jung

doi:https://doi.org/10.14449/jbd.2016.4.2.108

추천

검색

자료유형: 학술저널

저자정보: Tong Moon (Division of Breast and Endocrine Surgery Department of Surgery Seoul Medical Center) Dong Hui Cho (Division of Breast and Endocrine Surgery Department of Surgery Seoul Medical Center) Jung Min Youn (Division of Breast and Endocrine Surgery Department of Surgery Korea University Hospital Korea Univ) Jae Bok Lee (Division of Breast and Endocrine Surgery Department of Surgery Korea University Hospital Korea Univ) Jeoung Won Bae (Division of Breast and Endocrine Surgery Department of Surgery Korea University Hospital Korea Univ) Seung Pil Jung (Division of Breast and Endocrine Surgery Department of Surgery Korea University Hospital Korea Univ)

저널정보: 한국유방암학회 Journal of Breast Disease Journal of Breast Disease 제4권 제2호

발행연도: 2016.12

수록면: 108 - 115 (8page)

DOI: https://doi.org/10.14449/jbd.2016.4.2.108

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Purpose: In the treatment of breast cancer, neoadjuvant chemotherapy (NAC) is useful to reduce breast cancer size before surgical intervention. Patients who achieve a pathologic complete response (pCR) to NAC have improved overall survival (OS). However, the relationship between prognosis and partial response is yet unclear. In this study, we evaluated prognostic factors and the tumor response ratio (TRR) method among patients who received NAC. Methods: Clinicopathologic factors were evaluated to predict OS. The TRR was calculated by dividing pathologic tumor size by clinical tumor size. TRRs were then categorized into four groups, and the survival times for the different TRR groups were compared using statistical evaluation. Results: Clinical N stage (p=0.02), overall stage (p=0.04), pathologic N stage (p=0.03), hormone receptor status (p=0.01), and lymphovascular invasion (p=0.02) were significantly associated with OS. Pathologic overall stage and TRR did not correlate with OS. Patients with a pCR exhibited the best survival rates using the current staging system and the TRR method. Conclusion: Clinicopathologic factors can be easily applied to predict OS, and clinicians could use these parameters until an accurate, simple, and highly discriminatory methods is developed to assess breast cancer patients with a partial.

#Breast neoplasms #Neoadjuvant therapy #Prognosis #Response

참고문헌 (21)

참고문헌 신청

Bonadonna G / 1978 / Are surgical adjuvant trials altering the course of breast cancer? / Semin Oncol 5:450~464

Kantarjian HM / 1984 / The management of locally advanced breast cancer: a combined modality approach / Eur J Cancer Clin Oncol 20:1353~1361

Rastogi P / 2008 / Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27 / J Clin Oncol 26:778~785

Berruti A / 2011 / International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010) / J Natl Cancer Inst Monogr 2011:147~151

Bonadonna G / 1990 / Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more / J Natl Cancer Inst 82:1539~1545

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!